Last updated: February 27, 2026
What is NDC 25021-0460?
NDC 25021-0460 corresponds to Voretigene neparvovec-rzyl (Luxturna), a gene therapy approved by the FDA in December 2017 to treat inherited retinal dystrophy caused by RPE65 mutations. The therapy involves delivering a functional copy of the RPE65 gene via an adeno-associated virus vector (AAV2).
Market Size and Demographics
Target Population
Luxturna targets patients with confirmed RPE65 mutation-associated retinal dystrophy, a rare inherited condition affecting approximately 1,000 to 2,000 patients in the U.S.
- Prevalence: Estimated at 1 in 200,000 to 300,000 individuals.
- Eligible Patients: Patients with confirmed biallelic RPE65 mutations, typically, children and young adults.
Diagnosed Patients
- Estimated diagnosed prevalence is approximately 35-50% of total RPE65 mutation patients.
- Forecasted U.S. patients (2023): around 350-1,000 individuals.
Global Market Potential
- Similar prevalence across Europe, Japan, and other markets suggests a global patient pool of roughly 2,000–4,000.
Current Market Landscape
Competitors
- No direct gene therapy competitors approved for RPE65 mutation.
- Off-label treatments or supportive care systems are not substitutes.
Payer Coverage
- Reimbursement negotiated through value-based agreements with payers.
- Price sensitivity remains a concern, but the high cost reflects the therapy's curative potential and R&D costs.
Price Analysis and Projections
Current Pricing
- The wholesale acquisition cost (WAC) for Luxturna set at approximately $425,000 per eye in the U.S.
- Total treatment cost: $850,000 for both eyes.
Cost Components
- The per-unit price includes manufacturing, personalized administration, and post-treatment monitoring.
- Indirect costs, such as diagnostics and follow-up, add to the overall expenditure.
Price Factors
- R&D investment exceeds $500 million.
- Rare disease status allows for high pricing under orphan drug incentives.
- Payer negotiations aim to align price with clinical value, especially replacing ongoing treatments with a one-time therapy.
Price Projections (2023–2030)
| Year |
Estimated Average Price (Per Eye) |
Rationale |
| 2023 |
$425,000 |
Current market price |
| 2025 |
$400,000 |
Potential slight reduction due to manufacturing efficiencies and increased market competition in gene therapy platforms |
| 2030 |
$350,000 |
Price erosion expected as biosimilars or reformulations emerge, and market expansion reaches more patients |
Note: The therapy's curative nature supports sustained high pricing, though negotiations and payer pressure could lead to modest downward adjustments.
Market Dynamics Impacting Price
- Manufacturing scalability: Investment in process improvements could lower costs.
- Regulatory environment: Future approvals for broader indications could dilute per-patient costs.
- Market access policies: Value-based pricing models could influence final reimbursement levels.
- Emerging therapies: Competitors developing similar gene therapies could drive prices down through market competition.
Volume and Revenue Projections
Assuming a gradual increase in diagnosed and treated patients:
| Year |
Estimated Patients Treated |
Total Revenue (USD millions) |
| 2023 |
150 |
127.5 |
| 2025 |
400 |
160 |
| 2030 |
800 |
280 |
These projections account for increasing patient access, improved diagnosis rates, and adjusted prices.
Regulatory and Policy Considerations
- Orphan drug tax credits and incentives sustain R&D investments.
- Price regulation initiatives by CMS and other agencies could impact future pricing.
- Expansion into broader indications may change the pricing and market strategy.
Key Takeaways
- The U.S. price remains around $425,000 per eye, totaling $850,000 per patient.
- Global market potential remains limited by rare mutation prevalence.
- Market growth depends on diagnosis rates, approval of expanded indications, and cost management.
- Price erosion is likely but will be moderated by the therapy’s curative model and regulatory incentives.
- Revenue projections suggest gradual scale-up with therapeutic adoption increasing through 2030.
FAQs
1. What factors influence the pricing of Luxturna?
Manufacturing costs, R&D expenses, rarity of the condition, regulatory environment, and value-based negotiations determine pricing.
2. How many patients worldwide are eligible for Luxturna?
Approximately 2,000 to 4,000 patients globally, with the U.S. accounting for a third of that.
3. Is the therapy covered by insurance?
Yes, coverage exists through payers, often negotiated with value-based agreements, but access may vary.
4. Are there emerging therapies that could impact Luxturna's market?
Yes, ongoing research into alternative gene therapies or gene editing approaches may influence future competition and pricing.
5. How might pricing change in the next decade?
Expect modest reductions due to manufacturing efficiencies, potential biosimilar entry, and expanded indications, but high-value pricing is maintained by the therapy's curative effect.
References
[1] U.S. Food and Drug Administration (FDA). (2017). FDA approves novel gene therapy to treat patients with inherited blindness.
[2] Ionis Pharmaceuticals. (2021). Market analysis for rare disease therapies.
[3] EvaluatePharma. (2022). 2022 World Preview of Pharmaceutical Market Trends.
[4] GoodRx Health. (2023). Pricing dynamics of gene therapies.
[5] Orphan Drugs. (2023). Market and approval landscape.
